S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Sell every Stock except ONE (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Sell every Stock except ONE (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Sell every Stock except ONE (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Sell every Stock except ONE (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Sell every Stock except ONE (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Sell every Stock except ONE (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Sell every Stock except ONE (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Sell every Stock except ONE (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Sell every Stock except ONE (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Sell every Stock except ONE (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Sell every Stock except ONE (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Sell every Stock except ONE (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
NYSE:BSX

Boston Scientific - BSX Stock Forecast, Price & News

$42.63
+0.20 (+0.47%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$42.20
$42.66
50-Day Range
$35.24
$42.63
52-Week Range
$34.98
$47.49
Volume
6.05 million shs
Average Volume
6.92 million shs
Market Capitalization
$60.94 billion
P/E Ratio
73.50
Dividend Yield
N/A
Price Target
$46.55

Boston Scientific MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.2% Upside
$46.55 Price Target
Short Interest
Healthy
0.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.25mentions of Boston Scientific in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$2.40 M Sold Last Quarter
Proj. Earnings Growth
11.36%
From $1.76 to $1.96 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

76th out of 1,119 stocks

Surgical & Medical Instruments Industry

6th out of 111 stocks

BSX stock logo

About Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $43.00 to $45.00 in a research report on Thursday, July 28th. Citigroup decreased their price objective on shares of Boston Scientific from $52.00 to $47.00 and set a "buy" rating on the stock in a research report on Tuesday, May 17th. Wolfe Research assumed coverage on shares of Boston Scientific in a research report on Tuesday, July 5th. They set an "outperform" rating and a $43.00 price target on the stock. BTIG Research increased their price target on shares of Boston Scientific from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, July 28th. Finally, Morgan Stanley reduced their price target on shares of Boston Scientific from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Friday, July 15th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $46.55.

Boston Scientific Stock Performance

NYSE:BSX opened at $42.63 on Friday. The business has a 50 day moving average price of $38.69 and a 200-day moving average price of $41.22. Boston Scientific has a fifty-two week low of $34.98 and a fifty-two week high of $47.49. The firm has a market cap of $60.94 billion, a PE ratio of 73.50, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.86 and a current ratio of 1.31.

Boston Scientific (NYSE:BSX - Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The medical equipment provider reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.02. Boston Scientific had a return on equity of 14.58% and a net margin of 7.16%. The company had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the firm posted $0.40 earnings per share. The firm's revenue was up 5.4% on a year-over-year basis. Equities research analysts predict that Boston Scientific will post 1.76 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Eric Francis Yves Thepaut sold 20,676 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $40.99, for a total value of $847,509.24. Following the completion of the sale, the executive vice president now owns 72,486 shares of the company's stock, valued at $2,971,201.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Wendy Carruthers sold 7,500 shares of the firm's stock in a transaction on Monday, August 15th. The stock was sold at an average price of $42.03, for a total transaction of $315,225.00. Following the completion of the transaction, the executive vice president now directly owns 117,413 shares in the company, valued at $4,934,868.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Francis Yves Thepaut sold 20,676 shares of the firm's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $40.99, for a total value of $847,509.24. Following the transaction, the executive vice president now owns 72,486 shares of the company's stock, valued at $2,971,201.14. The disclosure for this sale can be found here. Insiders sold 59,264 shares of company stock valued at $2,401,673 over the last quarter. 0.71% of the stock is owned by company insiders.

Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Medtronic Stock Keeps Ticking Forward (BSX)
Medical device maker Medtronic (NYSE: MDT) stock is trading down (-14%) for the year.
Boston Scientific Co. (NYSE:BSX) EVP Sells $847,509.24 in Stock
Boston Scientific (NYSE:BSX) PT Raised to $50.00
Boston Scientific (NYSE:BSX) PT Raised to $45.00
See More Headlines
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Company Calendar

Last Earnings
7/27/2022
Today
8/19/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
10113710
Employees
41,000
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$46.55
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+9.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$1.04 billion
Pretax Margin
8.95%

Debt

Sales & Book Value

Annual Sales
$11.89 billion
Cash Flow
$2.72 per share
Book Value
$12.07 per share

Miscellaneous

Outstanding Shares
1,429,570,000
Free Float
1,419,421,000
Market Cap
$60.94 billion
Optionable
Optionable
Beta
0.85

Social Links


Key Executives

  • Mr. Michael F. MahoneyMr. Michael F. Mahoney (Age 57)
    Chairman, Pres & CEO
    Comp: $3.83M
  • Mr. Daniel J. BrennanMr. Daniel J. Brennan (Age 56)
    Exec. VP & CFO
    Comp: $1.4M
  • Mr. Joseph M. Fitzgerald (Age 58)
    Exec. VP & Group Pres of Cardiology
    Comp: $1.57M
  • Mr. Jeffrey B. MirvissMr. Jeffrey B. Mirviss (Age 56)
    Exec. VP & Pres of Peripheral Interventions
    Comp: $1.21M
  • Mr. John Bradley SorensonMr. John Bradley Sorenson (Age 54)
    Exec. VP of Global Operations
  • Mr. Jonathan R MonsonMr. Jonathan R Monson
    VP, Global Controller & Chief Accounting Officer
  • Ms. Jodi Euerle EddyMs. Jodi Euerle Eddy (Age 49)
    Sr. VP and Chief Information & Digital Officer
  • Ms. Susan Vissers Lisa (Age 53)
    VP of Investor Relations
  • Mr. Vance R. Brown
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Catherine Jennings
    VP of Global Marketing & New Bus. Devel. of Peripheral Interventions













BSX Stock - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BSX shares.
View BSX analyst ratings
or view top-rated stocks.

What is Boston Scientific's stock price forecast for 2022?

12 Wall Street analysts have issued 12-month target prices for Boston Scientific's shares. Their BSX share price forecasts range from $43.00 to $51.00. On average, they expect the company's share price to reach $46.55 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts price targets for BSX
or view top-rated stocks among Wall Street analysts.

How have BSX shares performed in 2022?

Boston Scientific's stock was trading at $42.48 at the start of the year. Since then, BSX shares have increased by 0.4% and is now trading at $42.63.
View the best growth stocks for 2022 here
.

Are investors shorting Boston Scientific?

Boston Scientific saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 13,750,000 shares, a decrease of 14.3% from the July 15th total of 16,040,000 shares. Based on an average daily trading volume, of 8,290,000 shares, the short-interest ratio is currently 1.7 days.
View Boston Scientific's Short Interest
.

When is Boston Scientific's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BSX earnings forecast
.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) released its quarterly earnings results on Wednesday, July, 27th. The medical equipment provider reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.02. The medical equipment provider earned $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. Boston Scientific had a net margin of 7.16% and a trailing twelve-month return on equity of 14.58%. The business's revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 EPS.
Read the conference call transcript
.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $0.43-$0.45 for the period, compared to the consensus EPS estimate of $0.45. The company issued revenue guidance of $3.11 billion-$3.17 billion, compared to the consensus revenue estimate of $3.20 billion.

What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?

947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (2.65%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (1.46%), Artisan Partners Limited Partnership (1.35%), Parnassus Investments LLC (1.10%), Northern Trust Corp (0.97%) and Lazard Asset Management LLC (0.89%). Insiders that own company stock include Arthur C Butcher, Arthur C Butcher, Daniel J Brennan, David A Pierce, David A Pierce, David S Wichmann, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Ian T Meredith, Jeffrey B Mirviss, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Maulik Nanavaty, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Wendy Carruthers, William F Bruss and Williamson Scott.
View institutional ownership trends
.

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $42.63.

How much money does Boston Scientific make?

Boston Scientific (NYSE:BSX) has a market capitalization of $60.94 billion and generates $11.89 billion in revenue each year. The medical equipment provider earns $1.04 billion in net income (profit) each year or $0.58 on an earnings per share basis.

How many employees does Boston Scientific have?

The company employs 41,000 workers across the globe.

Does Boston Scientific have any subsidiaries?
The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More
When was Boston Scientific founded?

Boston Scientific was founded in 1979.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The official website for the company is www.bostonscientific.com. The medical equipment provider can be reached via phone at (508) 683-4000, via email at bsxinvestorrelations@bsci.com, or via fax at 508-683-5675.

This page (NYSE:BSX) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.